Nordic Nanovector

Presentations at European Association of Nuclear Medicine Annual Meeting (EANM)

OSLO, Norway, Oct. 23, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the following presentations by the company's research collaborators at the European Association of Nuclear Medicine annual meeting (EANM; 21-25 October; Vienna, Austria).

Abstract:  OP-012

Title: Pre-dosing with lilotomab prior to antibody-radionuclide conjugate therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumour to red marrow absorbed dose in non-Hodgkin lymphoma patients Authors:  J. Blakkisrud et al.

Abstract: OP-054

Title: Involvement of cell cycle checkpoints in the therapeutic efficacy of 177Lu-lilotomab in non-Hodgkin B-cell lymphoma Authors:  A. Pichard et al.

Abstract: EP-0814

Title: FDG uptake at baseline may predict absorbed dose in tumor lesions in indolent Non-Hodgkin lymphoma patients treated with the novel antibody-radionuclide conjugate 177Lu-lilotomab satetraxetan Authors: A. Londalen et al.

In addition, Jostein Dahle, Nordic Nanovector's CSO presented in Pre-Congress Symposium 3 - Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities

Title: PS23 - Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies

The abstracts are available by clicking here

For further information, please contact:
IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: [phone]
Email: [e-mail]

Media enquiries:
Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson)
Tel: [phone]
Email: [e-mail]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.